Cost-effectiveness of paliperidone palmitate versus olanzapine, quetiapine and ziprazidone for the treatment of patients with schizophrenia under the brazilian private health care system perspective
May 1, 2014, 00:00
10.1016/j.jval.2014.03.1269
https://www.valueinhealthjournal.com/article/S1098-3015(14)01320-5/fulltext
Title :
Cost-effectiveness of paliperidone palmitate versus olanzapine, quetiapine and ziprazidone for the treatment of patients with schizophrenia under the brazilian private health care system perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)01320-5&doi=10.1016/j.jval.2014.03.1269
First page :
A217
Section Title :
Mental Health
Open access? :
No
Section Order :
731